Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19
Pfizer
AUGUST 15, 2022
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. IMPORTANT SAFETY INFORMATION.
Let's personalize your content